PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model
Cannabis Investing PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund
Cannabis Investing PreveCeutical Announces the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program
Cannabis Investing PreveCeutical Reaches Milestone in Research Program for Development of Non-Addictive Analgesics
Cannabis Investing PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property
Cannabis Investing PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System
PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program
PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program
Cannabis Investing PreveCeutical Announces Further Results from its Preliminary Screening of Peptides Derived from Blue Scorpion Venom in a Cell-Based Brain Cancer Model
Noble Mineral highlights Successful Exploration Results announced by Canada Nickel, including Highest Grade to Date at Mann West
CHARBONE Hydrogen and ABB Sign Agreement to Advance North American Green Hydrogen Production Facilities
